The Oncology Digital Patient Clone: Changing Approach to Evidence
Big pharma is increasingly doubling down on bets to develop new blockbuster cancer drugs, as approximately 700 organizations currently have one or more oncology drugs in late-stage development. Oncology continues to remain the most dominant therapy segment, and this has resulted in resulting in an increase in R&D expenditures to discover novel cancer drugs.
With these new opportunities comes a shift in data and evidence requirements as well. In this research paper from Ciox, readers can learn about innovative, life-extending therapies that are being launched in this area, the FDA’s evolution to enhance and streamline the regulatory process, and what the future looks like as EHR data gets extracted to develop a longitudinal view of the patient, thereby gaining a deeper understanding of what’s happening in the real world.